CSTL Stock Analysis: Castle Biosciences | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 734m USD | 12M Return: 19.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.22M
Qual. Beats: 0
Rev. Trend: 90.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Castle Biosciences is a molecular diagnostics company that develops and commercializes gene expression profile (GEP) tests and related tissue-based assays. Its flagship DecisionDx-Melanoma test predicts the risk of sentinel lymph node positivity and metastasis in invasive cutaneous melanoma, while DecisionDx-SCC addresses risk stratification in cutaneous squamous cell carcinoma. The company has expanded into adjacent indications with TissueCypher for Barretts esophagus, AdvanceAD-Tx for atopic dermatitis, and DecisionDx-UM for uveal melanoma, selling primarily to dermatology and gastroenterology practices. Founded in 2007 and headquartered in Friendswood, Texas, Castle Biosciences went public on Nasdaq in 2019.
As a clinical GEP-based diagnostics business, the company operates in the dermatology and gastroenterology markets, generating revenue primarily through per-test reimbursement from commercial and Medicare payers. Because the tests are physician-ordered and patient-specific, the business model relies on clinical adoption, inclusion in treatment guidelines, and favorable coverage decisions to drive recurring test volume.
- DecisionDx-Melanoma test volume growth drives dermatology segment revenue
- TissueCypher Barretts esophagus adoption accelerates gastroenterology sales
- NCCN guideline inclusion expands reimbursement coverage and physician adoption
| Net Income: -12.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -7.50 > 1.0 |
| NWC/Revenue: 82.41% < 20% (prev 89.92%; Δ -7.51% < -1%) |
| CFO/TA 0.09 > 3% & CFO 48.3m > Net Income -12.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.9m) vs 12m ago 4.47% < -2% |
| Gross Margin: 77.07% > 18% (prev 81.94%; Δ -4.87% > 0.5%) |
| Asset Turnover: 64.78% > 50% (prev 69.18%; Δ -4.40% > 0%) |
| Interest Coverage Ratio: -86.09 > 6 (EBIT TTM -17.5m / Interest Expense TTM 203k) |
| A: 0.51 (Total Current Assets 328.9m - Total Current Liabilities 48.8m) / Total Assets 547.8m |
| B: -0.44 (Retained Earnings -238.8m / Total Assets 547.8m) |
| C: -0.03 (EBIT TTM -17.5m / Avg Total Assets 524.8m) |
| D: 5.34 (Book Value of Equity 461.4m / Total Liabilities 86.4m) |
| Altman-Z'' = 7.32 = AAA |
| DSRI: 0.77 (Receivables 42.3m/56.4m, Revenue 339.9m/347.1m) |
| GMI: 1.06 (GM 81.94% / 77.07%) |
| AQI: 1.11 (AQ_t 0.19 / AQ_t-1 0.17) |
| SGI: 0.98 (Revenue 339.9m / 347.1m) |
| TATA: -0.11 (NI -12.8m - CFO 48.3m) / TA 547.8m) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 23.72 with a total of 200,770 shares traded. Over the past week, the price has changed by -1.62%, over one month by +12.52%, over three months by +2.55% and over the past year by +19.56%.
Current recommended Stop Loss: 22.50 (which is 5.1% or 1.2 ATR below the current price).
Castle Biosciences has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CSTL.
- StrongBuy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 43.6 | 83.6% |
P/S = 2.1602
P/B = 1.5848
Revenue TTM = 339.9m USD
EBIT TTM = -17.5m USD
EBITDA TTM = -726k USD
Long Term Debt = 8.40m USD (from longTermDebt, last quarter)
Short Term Debt = 2.92m USD (from shortTermDebt, last quarter)
Debt = 63.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 26.7m
Net Debt = -198.3m USD (calculated: Debt 63.4m - CCE 261.7m)
Enterprise Value = 536.0m USD (734.3m + Debt 63.4m - CCE 261.7m)
Interest Coverage Ratio = -86.09 (Ebit TTM -17.5m / Interest Expense TTM 203k)
EV/FCF = 118.6x (Enterprise Value 536.0m / FCF TTM 4.52m)
FCF Yield = 0.84% (FCF TTM 4.52m / Enterprise Value 536.0m)
FCF Margin = 1.33% (FCF TTM 4.52m / Revenue TTM 339.9m)
Net Margin = -3.78% (Net Income TTM -12.8m / Revenue TTM 339.9m)
Gross Margin = 77.07% ((Revenue TTM 339.9m - Cost of Revenue TTM 77.9m) / Revenue TTM)
Gross Margin QoQ = 72.15% (prev 78.95%)
Tobins Q-Ratio = 0.98 (Enterprise Value 536.0m / Total Assets 547.8m)
Interest Expense / Debt = 0.32% (Interest Expense 203k / Debt 63.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -13.8m (EBIT -17.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.75 (Total Current Assets 328.9m / Total Current Liabilities 48.8m)
Debt / Equity = 0.14 (Debt 63.4m / totalStockholderEquity, last quarter 461.4m)
Debt / EBITDA = 273.3 (negative EBITDA) (Net Debt -198.3m / EBITDA -726k)
Debt / FCF = -43.89 (Net Debt -198.3m / FCF TTM 4.52m)
Total Stockholder Equity = 463.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.45% (Net Income -12.8m / Total Assets 547.8m)
RoE = -2.77% (Net Income TTM -12.8m / Total Stockholder Equity 463.7m)
RoCE = -3.70% (EBIT -17.5m / Capital Employed (Equity 463.7m + L.T.Debt 8.40m))
RoIC = -2.85% (negative operating profit) (NOPAT -13.8m / Invested Capital 485.0m)
WACC = 5.97% (E(734.3m)/V(797.7m) * Re(6.46%) + D(63.4m)/V(797.7m) * Rd(0.32%) * (1-Tc(0.21)))
Discount Rate = 6.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 51.11 | Cagr: 4.38%
[DCF] Terminal Value 73.10% ; FCFF base≈19.4m ; Y1≈17.0m ; Y5≈13.8m
[DCF] Fair Price = 13.82 (EV 220.8m - Net Debt -198.3m = Equity 419.1m / Shares 30.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 90.01 | Revenue CAGR: 29.36% | SUE: 0.74 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.40 | Chg30d=-1.18% | Revisions=-36% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.30 | Chg30d=-1.44% | Revisions=-36% | Analysts=9
EPS current Year (2026-12-31): EPS=-1.40 | Chg30d=-1.40% | Revisions=-18% | GrowthEPS=-69.2% | GrowthRev=+2.5%
EPS next Year (2027-12-31): EPS=-0.93 | Chg30d=-0.35% | Revisions=-36% | GrowthEPS=+33.5% | GrowthRev=+11.6%
[Analyst] Revisions Ratio: -40% (up=9, down=23)